MGB-BP-3

• CAT Number: I007978
• CAS Number: 1000277-08-6
• Molecular Formula: C36H37N7O4
• Molecular Weight: 631.73
• Purity: ≥95%
• Synonyms: MGB-BP-3; MGBBP3; MGB BP 3;(E)-1-methyl-4-(1-methyl-4-(4-(2-(quinolin-3-yl)vinyl)benzamido)-1H-pyrrole-2-carboxamido)-N-(2-morpholinoethyl)-1H-pyrrole-2-carboxamide
• Target: Bacterial
• Solubility: Soluble in DMSO
• Storage: Store at -20°C
• IUPAC Name: 1-methyl-N-[1-methyl-5-(2-morpholin-4-ylethylcarbamoyl)pyrrol-3-yl]-4-[[4-[(E)-2-quinolin-3-ylethenyl]benzoyl]amino]pyrrole-2-carboxamide
• InChI: InChI=1S/C36H37N7O4/c1-41-24-30(20-32(41)35(45)37-13-14-43-15-17-47-18-16-43)40-36(46)33-21-29(23-42(33)2)39-34(44)27-11-9-25(10-12-27)7-8-26-19-28-5-3-4-6-31(28)38-22-26/h3-12,19-24H,13-18H2,1-2H3,(H,37,45)(H,39,44)(H,40,46)/b8-7+
• InChIKey: OEKXCVYZBVOWBR-BQYQJAHWSA-N
• SMILES: CN1C=C(C=C1C(=O)NC2=CN(C(=C2)C(=O)NCCN3CCOCC3)C)NC(=O)C4=CC=C(C=C4)/C=C/C5=CC6=CC=CC=C6N=C5

MGB-BP-3（Cat No.:I007978）is a novel antibiotic belonging to the Minor Groove Binder (MGB) class, developed by MGB Biopharma for treating Clostridioides difficile infections (CDI). It exhibits rapid bactericidal activity by binding to the minor groove of bacterial DNA, disrupting essential processes. In Phase II clinical trials, MGB-BP-3 demonstrated a 100% initial cure rate and a 95% sustained cure rate, with minimal recurrence and preservation of gut microbiota. Following a successful End-of-Phase 2 meeting with the FDA, it is poised to enter Phase III trials, aiming to become a first-line treatment for CDI.